Gilead Sciences, an American biopharmaceutical company, agreed to invest $200m in Arcus Biosciences, an oncology-focused biopharmaceutical company, as part of a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. "We believe Gilead is an ideal partner for Arcus with its focus on thoughtful and purposeful science, vision to provide transformational therapies in the oncology setting and deeply experienced scientific leadership. This collaboration will allow us to act as one team to maximize the clinical and commercial potential of Arcus’s therapeutic development candidates, greatly amplifying and expediting the opportunities in our pipeline and discovery programs. At the same time, this partnership structure facilitates Arcus’s path to becoming an independent, fully integrated biopharmaceutical company," Terry Rosen, Arcus CEO.